These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18020551)

  • 1. Tetravalent human-rhesus reassortant rotavirus vaccine: a review of its immunogenicity, tolerability and protective efficacy against paediatric rotavirus gastroenteritis.
    Foster RH; Wagstaff AJ
    BioDrugs; 1998 Feb; 9(2):155-78. PubMed ID: 18020551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.
    Vesikari T; Karvonen AV; Majuri J; Zeng SQ; Pang XL; Kohberger R; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
    J Infect Dis; 2006 Aug; 194(3):370-6. PubMed ID: 16826486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. US Rotavirus Vaccine Efficacy Group.
    Rennels MB; Wasserman SS; Glass RI; Keane VA
    Pediatrics; 1995 Dec; 96(6):1132-6. PubMed ID: 7491235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis.
    Joensuu J; Koskenniemi E; Pang XL; Vesikari T
    Lancet; 1997 Oct; 350(9086):1205-9. PubMed ID: 9652561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea.
    Linhares AC; Lanata CF; Hausdorff WP; Gabbay YB; Black RE
    Pediatr Infect Dis J; 1999 Nov; 18(11):1001-6. PubMed ID: 10571438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotavirus vaccines and vaccination in Latin America.
    Linhares AC; Bresee JS
    Rev Panam Salud Publica; 2000 Nov; 8(5):305-31. PubMed ID: 11190969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru.
    Lanata CF; Black RE; Flores J; Lazo F; Butron B; Linares A; Huapaya A; Ventura G; Gil A; Kapikian AZ
    Vaccine; 1996 Feb; 14(3):237-43. PubMed ID: 8920706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations.
    Santosham M; Moulton LH; Reid R; Croll J; Weatherholt R; Ward R; Forro J; Zito E; Mack M; Brenneman G; Davidson BL
    J Pediatr; 1997 Oct; 131(4):632-8. PubMed ID: 9386673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group.
    Dennehy PH; Rodgers GC; Ward RL; Markwick AJ; Mack M; Zito ET
    Pediatr Infect Dis J; 1996 Nov; 15(11):1012-8. PubMed ID: 8933551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotavirus G serotypes and p[],G genotypes identified in cases of reinfection among children participating in a trial with rhesus-human reassortant tetravalent vaccine (RRV-TV) in Belém, Brazil.
    Mascarenhas JD; Leite JP; Gabbay YB; Freitas RB; Oliveira CS; Monteiro TA; Linhares AC
    J Trop Pediatr; 2002 Apr; 48(2):93-7. PubMed ID: 12022436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.
    Rennels MB; Glass RI; Dennehy PH; Bernstein DI; Pichichero ME; Zito ET; Mack ME; Davidson BL; Kapikian AZ
    Pediatrics; 1996 Jan; 97(1):7-13. PubMed ID: 8545227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group.
    Ward RL; Bernstein DI
    Vaccine; 1995 Sep; 13(13):1226-32. PubMed ID: 8578808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of rotavirus vaccine trials in Finland.
    Vesikari T; Joensuu J
    J Infect Dis; 1996 Sep; 174 Suppl 1():S81-7. PubMed ID: 8752295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?
    Haber P; Chen RT; Zanardi LR; Mootrey GT; English R; Braun MM;
    Pediatrics; 2004 Apr; 113(4):e353-9. PubMed ID: 15060267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis.
    Pang XL; Joensuu J; Hoshino Y; Kapikian AZ; Vesikari T
    J Clin Virol; 1999 Jun; 13(1-2):9-16. PubMed ID: 10405887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants.
    Joensuu J; Koskenniemi E; Vesikari T
    Pediatr Infect Dis J; 1998 Apr; 17(4):334-40. PubMed ID: 9576390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal administration of rhesus rotavirus tetravalent vaccine.
    Vesikari T; Karvonen A; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
    Pediatr Infect Dis J; 2006 Feb; 25(2):118-22. PubMed ID: 16462287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
    Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
    Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public health considerations for the introduction of new rotavirus vaccines for infants: a case study of tetravalent rhesus rotavirus-based reassortant vaccine.
    Clemens J; Keckich N; Naficy A; Glass R; Rao M
    Epidemiol Rev; 1999; 21(1):24-42. PubMed ID: 10520471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.